Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Schirmers of \< 5 mm at 5 minutes~* TFBUT: less than 10 seconds~* Corneal staining of \>3 of 15: conjunctival staining of \>3 of 18~* Ocular Surface Disease Index of \> 50~* Presumed best corrected vision of 20/60 or better~Exclusion Criteria:~* Acute or inflammatory corneal disease~* Pregnancy or lactation~* Monocular status~* Punctal occlusion within 30 days~* Ocular surgery within 3 months~* Corneal thinning of \>50%~* Active corneal infection~* History of ocular malignancy~* Retinal neovascularization~* Current use of topical cyclosporin A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin Beta 4 eye drops (Type: EXPERIMENTAL): It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
- Vehicle Control (Type: PLACEBO_COMPARATOR): It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).